Editorial Policies
- Conflict of Interest and Financial Disclosures (specific to editors)
- Editorial Policies
- Advertisement Policies
- Publication Ethics and Malpractice Statement
- Publisher Policies
- COPE Recommendation for Plagiarism
- Peer Review Process
- Creative Commons License
- COPE Recommendation for Conflict of Interest (specific to editors)
- Editorial Process
- Conflict of Interest and Financial Disclosures (Specific to Editors)
To ensure impartiality and transparency in the editorial process, the International Journal of Pharmaceutical Sciences Letters (IJPSL) requires editors to disclose any potential conflicts of interest (COI). A COI may arise when an editor has a financial, professional, or personal relationship that could bias their decision-making regarding a manuscript.
Key components of this policy:
- Disclosure: Editors must disclose any financial or personal relationships that could influence their editorial decisions. This includes financial support from industry groups, personal relationships with authors or institutions, and any other relevant affiliations.
- Recusal: If an editor has a conflict of interest in relation to a submitted manuscript (e.g., they are an author or have a financial interest), they must recuse themselves from handling the manuscript, ensuring that an unbiased decision-making process is maintained.
- Managing COIs: The editorial board will evaluate any disclosed conflicts and determine how best to handle them to prevent bias in the review process. In cases of significant conflict, the editorial team may assign another editor to oversee the manuscript.
This policy is designed to maintain the integrity and transparency of the editorial process, ensuring that all decisions are made based on the merit of the research rather than personal interests.
2. Editorial Policies
The International Journal of Pharmaceutical Sciences Letters (IJPSL) maintains a set of editorial policies that guide the peer review, manuscript handling, and publication processes. These policies ensure consistency, transparency, and fairness in all editorial decisions.
Key elements of the editorial policies include:
- Peer Review Process: All submitted manuscripts undergo a double-blind peer review, where both the authors' and reviewers' identities are kept anonymous to prevent bias.
- Fairness and Transparency: The editorial team is committed to ensuring that all manuscripts are reviewed fairly based on their scientific merit and relevance to the field of pharmaceutical sciences.
- Decision-Making: Editors make decisions based on peer reviewer feedback and their own evaluation of the manuscript, ensuring that authors receive constructive feedback and timely decisions.
The editorial policies ensure that the publication process is fair, transparent, and in line with international academic standards
3. Advertisement Policies
The International Journal of Pharmaceutical Sciences Letters (IJPSL) does not accept paid advertisements or commercial sponsorships that could compromise the academic integrity of the journal. However, the journal may feature advertisements related to the field of pharmaceutical sciences in a clear and transparent manner, ensuring they do not influence the content or editorial decisions.
Key components of the advertisement policy include:
- Separation of Content: Advertisements will be clearly separated from research articles and editorial content to avoid any confusion.
- Editorial Independence: The journal’s editorial process will not be influenced by any commercial advertising or sponsorship.
- Ethical Advertising: Any advertisements included in the journal will comply with ethical standards and relevant advertising regulations.
This policy ensures that the journal remains focused on publishing high-quality, unbiased academic research.
4. Publication Ethics and Malpractice Statement
The International Journal of Pharmaceutical Sciences Letters (IJPSL) is committed to maintaining the highest standards of publication ethics and preventing misconduct. The journal adheres to the ethical principles set out by the COPE (Committee on Publication Ethics), ensuring that all published research is original, properly attributed, and free from plagiarism or falsification.
The journal's ethical and malpractice policies include:
- Plagiarism and Duplicate Publication: Any form of plagiarism (including self-plagiarism) is not tolerated. Manuscripts are checked for plagiarism, and any detected cases of unethical conduct will lead to rejection or retraction of the article.
- Data Falsification: The journal condemns any form of data fabrication or manipulation. Authors must provide authentic and transparent research data, and any falsification detected will lead to rejection and possible reporting to relevant institutions.
- Authorship: Authors must be those who have made significant intellectual contributions to the research. All co-authors should have agreed to the final version of the manuscript and be accountable for the work.
- Retraction and Corrections: If serious ethical violations are identified after publication, the article may be retracted or corrected. The journal follows COPE guidelines for retraction, ensuring full transparency and responsibility.
By maintaining a clear stance on publication ethics, the IJPSL ensures that its research maintains credibility and trustworthiness in the scientific community.
5. Publisher Policies
The International Journal of Pharmaceutical Sciences Letters (IJPSL) has a set of publisher policies that govern all aspects of the journal’s operation, including editorial independence, peer review procedures, and open access publishing.
Key points of the publisher policies include:
- Open Access: The journal follows an open access publishing model, meaning all articles are freely accessible to readers upon publication, with no subscription fees.
- Editorial Independence: The publisher ensures that editorial decisions are made solely based on the scientific merit of the work, without any interference from commercial interests or outside parties.
- Compliance with Ethical Standards: The journal complies with international ethical guidelines for publishing, including those set by the COPE and other relevant organizations.
- Copyright and Licensing: The journal supports Creative Commons licensing, which allows authors to retain copyright and control over how their work is shared and used.
Publisher policies are designed to ensure transparency, quality, and ethical practices in all aspects of the journal’s operation.
6. COPE Recommendation for Plagiarism
The International Journal of Pharmaceutical Sciences Letters (IJPSL) follows the COPE (Committee on Publication Ethics) recommendations for addressing plagiarism. The journal uses plagiarism detection software to screen all submitted manuscripts for potential plagiarism and takes any detected cases very seriously.
Key aspects of the plagiarism policy:
- Prevention: Manuscripts are screened for plagiarism before they are sent out for peer review.
- Detection: If any plagiarism is detected, the manuscript may be rejected outright, or the authors may be asked to provide clarification or make revisions.
- Action: If plagiarism is discovered post-publication, the journal will follow the COPE guidelines for retraction, which may include issuing a formal retraction notice or publishing a correction.
The journal ensures that all published works are original and contribute genuinely to the body of scientific knowledge.
7. Peer Review Process
The International Journal of Pharmaceutical Sciences Letters (IJPSL) follows a rigorous and transparent peer review process to ensure the quality and integrity of the published research. The journal uses a double-blind peer review model, where the identities of both authors and reviewers are kept confidential throughout the review process.
Key steps in the peer review process include:
- Initial Screening: Upon submission, the manuscript is screened for relevance to the journal's scope, originality, and adherence to submission guidelines.
- Reviewer Selection: The editorial team selects experts in the field of pharmaceutical sciences to review the manuscript. These experts evaluate the quality, novelty, and scientific rigor of the work.
- Reviewer Feedback: Reviewers provide detailed comments on the manuscript, which may include suggestions for revision or improvement. The authors are then given an opportunity to address the reviewers' comments and revise the manuscript.
- Decision: Based on the reviewers' feedback and the editor's assessment, the manuscript may be accepted, revised, or rejected. In some cases, additional rounds of revision may be required.
The peer review process ensures that only high-quality, scientifically sound research is published in the journal.
8. Creative Commons License
The International Journal of Pharmaceutical Sciences Letters (IJPSL) uses Creative Commons (CC) licenses to enable open access to published research while allowing authors to retain copyright. This ensures that articles are freely accessible to anyone with an internet connection and can be reused or adapted according to the terms of the chosen license.
The available CC licenses are:
- CC BY (Attribution): This is the most permissive license, allowing others to distribute, remix, and build upon the work for any purpose, as long as the original author is credited.
- CC BY-NC (NonCommercial): This license allows others to remix and build upon the work for non-commercial purposes only, with proper attribution.
- CC BY-NC-ND (NonCommercial-NoDerivatives): This license allows others to download the works and share them, but not to modify them in any way and only for non-commercial purposes.
By using Creative Commons licenses, the journal ensures that research is disseminated freely and that authors retain the rights to their work, while also enabling others to build upon and share the research.
9. COPE Recommendation for Conflict of Interest (Specific to Editors)
The International Journal of Pharmaceutical Sciences Letters (IJPSL) adheres to the COPE recommendations regarding conflicts of interest (COI) for editors. Editors are expected to disclose any conflicts of interest that could affect their impartiality in making editorial decisions.
Key aspects of this policy include:
- Disclosure: Editors must disclose any financial or personal relationships that could be perceived as a conflict of interest. This includes relationships with authors, institutions, or funding agencies.
- Recusal: Editors are required to recuse themselves from handling manuscripts where they have a conflict of interest to ensure unbiased decision-making.
- Managing COIs: In cases where a conflict of interest exists, the editorial board will make the necessary adjustments to ensure that editorial decisions are not influenced by personal or financial interests.
10. Editorial Process
The International Journal of Pharmaceutical Sciences Letters (IJPSL) follows a systematic editorial process from submission to publication. The editorial team ensures that all manuscripts are handled ethically, efficiently, and transparently.
Steps in the editorial process include:
- Submission: Authors submit manuscripts via the journal's online submission system, ensuring that all necessary documents and information are included.
- Initial Screening: The editorial team screens the manuscript for relevance, originality, and adherence to submission guidelines. Manuscripts that do not meet the journal's requirements are returned to the authors.
- Peer Review: Manuscripts that pass the initial screening are sent for double-blind peer review. The review process typically takes 2-4 weeks.
- Decision and Revision: The editor makes a decision based on the peer reviews and provides feedback to the authors. Authors may be asked to revise their manuscript and resubmit it for further review.
- Publication: Once accepted, the manuscript is processed for publication, including copyediting, typesetting, and final proofreading before being published online.
The editorial process ensures that all manuscripts undergo thorough scrutiny before being accepted for publication.
